XNAS · LENZ
0.00% · $0.0000 · Vol Not reported
Pre-market · updated 06:08:04 ET
LENZ Therapeutics, Inc. Common Stock

LENZ Therapeutics, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$3.62
Card
Relationship Map

Follow $LENZ

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $LENZ by email

Veridion Score

BETAHIGH CONF · 6 of 6 factors measuredMethodology
LENZ
LENZ Therapeutics, Inc. Common Stock
Wed Oct 7 · last completed session · Pre-market · regular session opens 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

55/ 100
Veridion Score
Middle range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Wed Oct 7 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is LENZ moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading LENZ catalysts
About LENZ Therapeutics, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2024
Employees
152
Country
US

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$3.62
Last session
Day high
$3.62
Last session
Day low
$3.62
Last session
Previous close
$3.62
52W high
$48.60
-92.55% from high
52W low
$3.58
0% of range
Market cap
$113.7M
Beta
0.42
Shares out
31.4M
Avg volume
737.3K
VWAP
$3.62
Last session
Price history computed in-house
1W
-4.49%
1M
-32.08%
3M
-35.24%
1Y
-92.55%
YTD
-77.38%
SMA 50 $4.67 · below
SMA 200 $9.14 · below
52W position 0%

LENZ overview

Veridion Score
55
Registered · 2026-10-07
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around LENZ.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading LENZ Form 4 filings
Public disclosures

Congress activity in LENZ

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

LENZ contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for LENZ in this window.
Lobbying spend

LENZ lobbying filings, year to date.

Registered lobbying filings matched to LENZ Therapeutics, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for LENZ in this window.
Loading news for LENZ
Analyst ratings
Sovereign unlock shows live analyst consensus for LENZ.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.